Nr-CAM gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors

• US 20060269558A1
• Filed: 06/01/2006
• Published: 11/30/2006
• Est. Priority Date: 04/27/1998
• Status: Abandoned Application

• Current Assignee: Alton L. Boynton, Anil Sehgal, Bridget Murphy, Gerald P. Murphy
• Original Assignee: Alton L. Boynton, Anil Sehgal, Bridget Murphy, Gerald P. Murphy
• Inventors: Murphy, Bridget, Boynton, Alton L., Murphy, Gerald P., Sehgal, Anil
• Application Number:
  US11/445,961
• Publication Number:
  US 20060269558A1
• Time in Patent Office: Days
• US Class Current: 424/155.100
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 33/57407 Specifically defined cancers

Abstract

The present invention relates to the identification of a novel role of Nr-CAM in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of Nr-CAM in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for Nr-CAM. Further, the present invention relates, in part, to the Applicants'"'"' surprising discovery that the inhibition of Nr-CAM gene expression or the inhibition of Nr-CAM activity in transformed cells reverses the transformed phenotype.

Claims

1. A composition for the inhibition of tumorigenesis comprising an antibody to Nr-CAM, or an antigen-binding fragment thereof, in an amount effective to inhibit hyperproliferation of a tumor cell having high Nr-CAM expression.

2. The composition of claim 1, wherein said antibody or antigen-binding fragment thereof has specificity for human Nr-CAM.

3. The composition of claim 1, wherein said antibody or antigen-binding fragment thereof is monoclonal.

4. The composition of claim 1, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of

(a) a chimeric antibody;

(b) a single chain antibody;

(c) an Fv fragment;

(d) a bi-specific antibody having specificity for (i) human Nr-CAM and (ii) a molecule identified as causing a cytotoxic T-cell response against a target cell; and

(e) an antibody or antigen-binding fragment thereof conjugated to a heterologous protein or peptide.

5. A method of treating, inhibiting, or preventing in a subject a disease or disorder involving overproliferation of cells having high Nr-CAM expression, said method comprising administering to a subject in which such treatment or prevention is desired an effective amount of a molecule that inhibits Nr-CAM function, wherein the molecule that inhibits Nr-CAM function is selected from the group consisting of

(a) an anti-Nr-CAM antibody or an antigen-binding fragment thereof;

(b) a Nr-CAM derivative or analog that is capable of being bound by an anti-Nr-CAM antibody; and

(c) a nucleic acid comprising at least a portion of a Nr-CAM gene into which a heterologous nucleotide sequence has been inserted such that said heterologous sequence inactivates the biological activity of at least a portion of the Nr-CAM gene, in which the Nr-CAM gene portion flanks the heterologous sequence so as to promote homologous recombination with a genomic Nr-CAM gene.

6. The method according to claim 5 in which the disease or disorder is a malignancy.

7. The method according to claim 5 in which the disease or disorder is selected from the group consisting of brain cancer, leukemia, and B cell lymphoma.

8. The method according to claim 7 in which the brain cancer is selected from the group consisting of glioblastoma, glioma, meningioma, astrocytoma, medulloblastoma, neuroectodermal cancer and neuroblastoma.

9. The method according to claim 8 in which the glioblastoma is glioblastoma multiforme.

10. The method according to claim 5 in which the disease or disorder is selected from the group consisting of premalignant conditions, benign tumors, hyperproliferative disorders, and benign dysproliferative disorders.

11. The method according to claim 5 in which the subject is a human.

12. A method of treating, inhibiting, or preventing in a subject a disease or disorder involving proliferation of cells expressing Nr-CAM, said method comprising administering to a subject in need of such treatment an effective amount of a molecule that promotes Nr-CAM function, wherein said molecule promoting Nr-CAM function is selected from the group consisting of

(a) an anti-Nr-CAM antibody or an antigen-binding fragment thereof, and

(b) a Nr-CAM derivative or analog that is capable of being bound by an anti-Nr-CAM antibody.

13. The method according to claim 12, in which the disease or disorder is selected from the group consisting of degenerative disorders, growth deficiencies, hypoproliferative disorders, physical trauma, lesions, and wounds.

14. A method of diagnosing a disease or disorder characterized by an aberrant level of Nr-CAM RNA or protein in a subject, comprising measuring the level of Nr-CAM RNA or protein in a sample derived from the subject, in which an increase or decrease in the level of Nr-CAM RNA or protein, relative to the level of Nr-CAM RNA or protein found in an analogous sample from another subject not having the disease or disorder, indicates the presence of the disease or disorder in the subject.

15. A method of diagnosing or screening for the presence of or a predisposition for developing a disease or disorder involving cell overproliferation in a subject comprising detecting Nr-CAM DNA, RNA or protein derived from the subject in which the presence of said Nr-CAM DNA, RNA or protein indicates the presence of the disease or disorder or a predisposition for developing the disease or disorder.

16. A kit comprising in one or more containers a molecule selected from the group consisting of an anti-Nr-CAM antibody and an anti-Nr-CAM ligand antibody.

17. A composition for the inhibition of tumorigenesis comprising an antibody to an Nr-CAM ligand, or an antigen-binding fragment of said antibody, in an amount effective to inhibit hyperproliferation of a tumor cell having high Nr-CAM expression.

18. A method of treating, inhibiting, or preventing in a subject a disease or disorder involving overproliferation of cells having high Nr-CAM expression, said method comprising administering to a subject in which such treatment or prevention is desired an effective amount of an antibody to an Nr-CAM ligand, or an antigen-binding fragment of said antibody, to inhibit an Nr-CAM ligand function.

19. A method of diagnosing a disease or disorder characterized by an aberrant level of an Nr-CAM ligand encoding RNA or protein in a subject, comprising measuring the level of an Nr-CAM ligand encoding RNA or protein in a sample derived from the subject, in which an increase or decrease in the level of said RNA or protein, relative to the level of said RNA or protein found in an analogous sample from another subject not having the disease or disorder, indicates the presence of the disease or disorder in the subject.

20. A method of diagnosing or screening for the presence of or a predisposition for developing a disease or disorder involving cell overproliferation in a subject comprising detecting an Nr-CAM ligand encoding DNA, RNA or protein derived from the subject in which the presence of said DNA, RNA or protein indicates the presence of the disease or disorder or a predisposition for developing the disease or disorder.